Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Cash (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Change in Cash for 9 consecutive years, with -$6.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Cash fell 158.49% year-over-year to -$6.2 million, compared with a TTM value of -$7.6 million through Jun 2025, down 184.97%, and an annual FY2025 reading of $4.1 million, up 138.16% over the prior year.
  • Change in Cash was -$6.2 million for Q2 2025 at VYNE Therapeutics, down from $8.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $61.0 million in Q1 2021 and bottomed at -$51.1 million in Q3 2021.
  • Average Change in Cash over 5 years is -$2.0 million, with a median of -$5.7 million recorded in 2023.
  • The sharpest move saw Change in Cash skyrocketed 429.68% in 2023, then plummeted 1562.59% in 2024.
  • Year by year, Change in Cash stood at -$10.1 million in 2021, then soared by 54.24% to -$4.6 million in 2022, then surged by 429.68% to $15.2 million in 2023, then tumbled by 76.23% to $3.6 million in 2024, then tumbled by 270.83% to -$6.2 million in 2025.
  • Business Quant data shows Change in Cash for VYNE at -$6.2 million in Q2 2025, $8.3 million in Q1 2025, and $3.6 million in Q4 2024.